BBA
AVTX icon

Baader Bank Aktiengesellschaft’s Avalo Therapeutics AVTX Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-768
Closed -$19.8K – 337
2023
Q3 		$19.8K Buy
+768
New +$34.3K ﹤0.01% 288

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
N
Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Baader Bank Aktiengesellschaft's AVTX Position: Q4 2023 in Review

Baader Bank Aktiengesellschaft sold out of Avalo Therapeutics (AVTX) in Q4 2023, closing a stake of 768 shares — an estimated $19.8K sold.

Baader Bank Aktiengesellschaft first reported a position in AVTX in Q3 2023 and held it in 1 quarter. The position peaked at $19.8K in Q3 2023. 12 funds tracked by Wall St. Rank hold AVTX as of Q4 2023.

  • Baader Bank Aktiengesellschaft reported no remaining Avalo Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 768 Avalo Therapeutics shares in Q4 2023, an estimated $19.8K.
  • Baader Bank Aktiengesellschaft first reported a position in Avalo Therapeutics in Q3 2023 and held it in 1 quarter.
  • Baader Bank Aktiengesellschaft's Avalo Therapeutics position peaked at $19.8K in Q3 2023.
  • 12 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2023.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q4 2023, filed 8 Feb 2024.